Case Report: Pathological Complete Response in a Lung Metastasis of Phyllodes Tumor Patient Following Treatment Containing Peptide Neoantigen Nano-Vaccine.
Case Report: Pathological Complete Response in a Lung Metastasis of Phyllodes Tumor Patient Following Treatment Containing Peptide Neoantigen Nano-Vaccine.
复制标题
病例报告：叶状肿瘤肺转移患者接受肽新抗原纳米疫苗治疗后病理完全缓解
DOI：
10.3389/fonc.2022.800484
复制
发表时间：
2022
影响因子：
4.7
通讯作者：
Liu B
中科院分区：
文献类型：
--
作者：
Sha H;Liu Q;Xie L;Shao J;Yu L;Cen L;Li L;Liu F;Qian H;Wei J;Liu B
基因突变转录和翻译产生的一些突变肽具有诱导特异性T细胞的能力，称为新抗原。基于新抗原的肽、DNA、RNA和树突状细胞疫苗已被用于临床。在本文中，我们描述了一个叶状肿瘤患者的肺转移，在含有个性化多表位肽新抗原纳米疫苗的治疗后表现出病理学完全应答。基于全外显子组测序（WES）、RNA测序和新抗原预测，预测几种突变的肽片段与患者的人类白细胞抗原（HLA）同种异型结合，包括对六种基因具有高预测结合亲和力的十种肽。在抗PD 1和安洛替尼的4个周期后，肺转移保持稳定。加入多表位肽新抗原纳米疫苗后，肿瘤开始塌陷，挛缩发展，伴随肿瘤标志物降至正常，达到完全病理缓解。在使用疫苗的同时，每次使用重组人粒细胞-巨噬细胞集落刺激因子（rhGM-CSF），每3周注射一次小剂量环磷酰胺，以提高疗效。外周血免疫监测证实了针对一系列肽的免疫反应性，其中针对HLA-DRB 1 *0901限制性SLC 44 A5 V54 F肽检测到最稳健的疫苗后T细胞应答。
Some of the mutant peptides produced by gene mutation transcription and translation have the ability to induce specific T cells, which are called new antigens. Neoantigen-based peptide, DNA, RNA, and dendritic cell vaccines have been used in the clinic. In this paper, we describe a lung metastasis of a phyllodes tumor patient demonstrating pathological complete response following treatment containing personalized multi-epitope peptide neoantigen nano-vaccine. Based on whole-exome sequencing (WES), RNA sequencing, and new antigen prediction, several mutated peptide fragments were predicted to bind to the patient’s human leukocyte antigen (HLA) allotypes, including ten peptides with high predicted binding affinity for six genes. The pulmonary metastases remained stable after the four cycles of anti-PD1 and anlotinib. After the addition of the multi-epitope peptide neoantigen nano-vaccine, the tumor began to collapse and contracture developed, accompanied by a decrease of tumor markers to normal, and complete pathological remission was achieved. With the use of the vaccination, recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was used every time, and low-dose cyclophosphamide was injected every 3 weeks to improve efficacy. Peripheral blood immune monitoring demonstrated immune reactivity against a series of peptides, with the most robust post-vaccine T-cell response detected against the HLA-DRB1*0901-restricted SLC44A5 V54F peptide.
登录
查看更多内容
影响因子：
82.9
作者：
通讯作者：
--
影响因子：
4.6
作者：
Zhang, Yanhong;Kleer, Celina G.
通讯作者：
Kleer, Celina G.
影响因子：
29.4
作者：
Keenan BP;Saenger Y;Kafrouni MI;Leubner A;Lauer P;Maitra A;Rucki AA;Gunderson AJ;Coussens LM;Brockstedt DG;Dubensky TW Jr;Hassan R;Armstrong TD;Jaffee EM
通讯作者：
Jaffee EM
影响因子：
82.9
作者：
Walter, Steffen;Weinschenk, Toni;Singh-Jasuja, Harpreet
通讯作者：
Singh-Jasuja, Harpreet
影响因子：
64.8
作者：
Hilf, Norbert;Kuttruff-Coqui, Sabrina;Wick, Wolfgang
通讯作者：
Wick, Wolfgang